Cancer Institute

  • Eddie Perkins

    Assistant Professor, Departments of Neurosurgery (adjunct appointment)
    Molecular Cancer Therapeutics
    BS, Biology, 1979, University of Mississippi
    PhD, Anatomy, 2006, University of Mississippi Medical Center

    Contact information 
    Department of Neurosurgery
    2500 N. State S., Room R732
    Jackson, MS 39216
    Pager: (601) 929-1343
    Email: eperkins@umc.edu  

     perkins_eddie.jpg

    Research interests

    • Use of thermally targeted therapeutic polypeptide for the treatment of brain cancer
    • Inhibition of calcium release-activated calcium (CRAC) channels in the treatment of brain cancer
    • Characterization of glioblastoma multiforme with bio-markers and clinical correlations

    Research synopsis

    The goal of the research is to develop and evaluate novel therapeutics for the treatment of malignant brain tumors. Glioblastoma multiforme (GBM) is the most aggressive form of primary brain tumor. Current treatment strategy for patients with GBM includes surgery to remove as much of the tumor as possible combined with chemotherapy and radiation therapy. However, even with aggressive treatment, survival is poor. Therefore, alternative treatment strategies that can kill or slow tumor cells growth is necessary. Our laboratory is investigating new therapies for treating brain tumors. One, is using therapeutic polypeptides which consist of three components, an inhibitor (H1), a thermal responsive unit (ELP) and a cell penetrating peptide (CPP) unit. This therapeutic construct is delivered directly to the cytoplasm or nuclei of cells in the tumor mass. Another therapy is the use of CRAC channels inhibitors to treat brain tumors. CRAC channels have a role in tumor cell proliferation and metastasis. Finally, Studies have shown that tumor formation, growth, aggression and invasion are associated with a number of cellular products and abnormal cellular changes. These include, in part, the production of growth factors, cytokines, matrix metalloproteases and chromosomal abnormalities. However, few of the studies that have evaluated the presence of multiple molecular markers have correlated the findings with the clinical outcomes of patients. Our studies directly addresses the relationship of multiple tumor markers to patient's clinical outcomes.

    Awards and honors

    • Evers Society M2 All-star Professor  (Teaching excellence), 2015 - 2016
    • Nelson Order, (Teaching excellence), 2015 - 2016
    • The Carl G. Evers, M.D., Society award "Course of the year," 2013
    • (Neurobiology, core faculty) Selected by M2 Students    
    • The Carl G. Evers, M.D., Society award "Course of the year," 2011
      (Neurobiology, core faculty) Selected by M2 Students

    Selected publications

    • Fusion of cell-penetrating peptides to thermally responsive biopolymer improves tumor accumulation of p21 peptide in a mouse model of pancreatic cancer. 
    • Thermally Targeted Delivery of a c-Myc Inhibitory Polypeptide Inhibits Tumor Progression and Extends Survival in a Rat Glioma Model. Bidwell GL III, Perkins E, Hughes J, Khan M, James JR, et al. (2013)  PLoS One 8(1), 2013 
    • Cell Penetrating Peptides Fused to a Thermally Targeted Biopolymer Drug Carrier Improve the Delivery and Antitumor Efficacy of an Acid-sensitive Doxorubicin Derivative. Walker L, Perkins E, Kratz F, Raucher D.  International Journal of Pharmaceutics 436:825-832, 2012 
    • Thermal Targeting of an Acid-Sensitive Doxorubicin Conjugate of Elastin-like Polypeptide Enhances the Therapeutic Efficacy Compared to the Parent Compound in vivo. Moktan S, Perkins E, Kratz F, Raucher D.  Molecular Cancer Therapeutics 11(7):547-1556, 2012 
    • A thermally targeted c-Myc inhibitory polypeptide inhibits breast tumor growth. Bidwell GL, Perkins E, Raucher D. Cancer Letters 319 (2):136-143, 2012 
    • Calcium entry via ORA1regulates glioblastoma cell proliferation and apoptosis. Huiling L, Hughes JD, Rollins S, Chen B, Perkins E.  Experimental and Molecular Pathology 91:753-760, 2011